What is the current valuation of Pfizer’s PF-07038124
The revenue for PF-07038124 is expected to reach an annual total of $13 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
PF-07038124 Overview
PF-07038124 is under development for the treatment of seborrheic dermatitis. It is formulated as an ointment and administered by topical route. It is a new molecular entity and acts by targeting phosphodiesterase 4 (PDE4).
It was under development for atopic dermatitis and plaque psoriasis.
Pfizer Overview
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
The company reported revenues of (US Dollars) US$100,330 million for the fiscal year ended December 2022 (FY2022), an increase of 23.4% over FY2021. In FY2022, the company’s operating margin was 36.1%, compared to an operating margin of 28.9% in FY2021. In FY2022, the company recorded a net margin of 31.3%, compared to a net margin of 27% in FY2021.
For a complete picture of PF-07038124’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Source link
#current #valuation #Pfizers #PF07038124